Categories: News

Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system (CNS), today announced that Adrian Adams, Chairman and CEO, will participate in a fireside chat at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference on Tuesday, November 16, 2021 at 1:40 p.m. ET.

A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the presentation will be available on the Impel NeuroPharma website following the event.

About Impel NeuroPharma

Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

Investor Relations:
Christina Tartaglia
Stern Investor Relations
Phone: (1) 212-362-1200
Email: christina.tartaglia@sternir.com

Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com

Staff

Recent Posts

What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives

Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…

9 hours ago

After Trump’s Marijuana Executive Order, Will the DEA Face a Court Imposed Deadline from MMJ’s Writ of Mandamus?

After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…

1 day ago

Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings

Boards and executive buyers are raising the 2026 bar for all product and service rankings…

1 day ago

Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings

Boards and executive buyers are raising the 2026 bar for all product and service rankings…

1 day ago

Awake Breast Augmentation: Gruber Plastic Surgery Highlights Live Implant Sizing Under Local Anesthesia With No Sedation for Eligible Patients

Tampa based Celebrity Board-Certified Plastic Surgeon Dr. Meegan Gruber expands an interactive approach that allows…

1 day ago